NightWare

NightWare operates in the specialized digital therapeutics segment rather than the broad consumer sleep-app market. Its differentiation is a prescription, FDA-cleared system focused specifically on traumatic nightmares associated with PTSD and Nightmare Disorder. The product uses an Apple Watch, heart-rate and movement signals, sleep-disturbance analysis, and adaptive vibration to intervene during a nightmare without necessarily waking the user. That combination gives NightWare a more clinically targeted position than general wellness applications such as Calm or Headspace, which are not comparable prescription devices and do not focus on automated nightmare intervention. This limits conclusions about relative market share, pricing, clinical evidence, and distribution. NightWare’s FDA Breakthrough Device designation in 2020 and its focus on veterans, service members, and civilians affected by trauma provide meaningful positioning in an area with high unmet need. However, its small disclosed employee range of one to ten people and $1.48 million in total disclosed funding suggest a specialized early-stage operating profile rather than a scaled digital-health platform.

NightWare’s growth trajectory shows gradual financing and product maturation, but not enough public operating data to establish rapid commercial expansion. The company was founded on Sep 27, 2015 and raised two seed rounds totaling $405,000 in 2019 and 2021. It then reported a $700,000 venture round on Jul 27, 2022, followed by $127,965 through equity crowdfunding on Dec 23, 2024 and another $250,000 venture round on Mar 6, 2026. The financing pattern indicates continued capital formation over seven years, with the latest round extending runway rather than signaling a large institutional financing event. Product development has advanced from a digital therapeutic concept to a prescription system built around Apple Watch biometric sensing, adaptive sleep-pattern analysis, and personalized vibration intervention. Patent activity in 2022 supports the company’s technical focus, while its 2020 FDA Breakthrough Device designation marks an important regulatory inflection point. The current team includes a co-founder and CEO, CMO, CTO, and chief scientific advisor, with an employee range of one to ten.